NCT06686966Completed
Prediction of Postoperative Complications and Survival in Gastric Cancer Using Preoperative Blood Markers
Clinical Study on the Effect of Preoperative Serum Biomarkers on the Prognosis of Gastric Cancer
Source: ClinicalTrials.gov · Last updated 3 Mar 2026
Brief summary (registry, in English)
Gastric cancer is one of the most common cancers worldwide, especially in East Asia. Although surgery remains the main treatment, patients may experience postoperative complications and have varying long-term survival outcomes. Early identification of high-risk patients before surgery is important for improving treatment decisions and patient management. This study aims to develop a prediction model based on routinely available preoperative blood test results and clinical characteristics to estimate the risk of postoperative complications and long-term survival in patients with gastric cancer. The model will be developed and validated using data from multiple medical centers. By using easily accessible clinical information, this study seeks to provide a practical tool to help clinicians better assess patient risk before surgery, support personalized treatment planning, and improve overall patient outcomes.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 3400 (actual)
- First submitted
- 12 Nov 2024
- Start date
- 1 Jan 2010
- Primary completion date
- 1 Nov 2024
- Lead sponsor
- First Affiliated Hospital of Chongqing Medical University
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT06686966
What you commit to
- Study type: Observational
- Participants enrolled: 3400
- From 1 Jan 2010 to the primary completion date, 1 Nov 2024
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- patients with other primary malignant tumours other than gastric cancer;
- patients with systemic diseases such as severe cardiopulmonary insufficiency that affect the choice of treatment plan;
Other
- patients who are not suitable for enrolment as assessed by the investigator;
- incomplete clinical data.
Who the study is looking for
- patients aged ≥18 years;
- patients diagnosed with gastric cancer by pathological biopsy before surgery;
- patients without chemotherapy, radiotherapy, targeted and immunotherapy before enrolment;
- willing to participate in this study and sign the informed consent;
- complete clinical data.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.